TFF PHARMACEUTICALS, INC. Deferred Tax Assets, in Process Research and Development
TFF PHARMACEUTICALS, INC. had Deferred Tax Assets, in Process Research and Development of $3.26 million as of 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2024-03-28
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $3.26M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $2.38M.
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $785.76K.
- 2021-09-30: Deferred Tax Assets, in Process Research and Development $1.11M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2023-12-31 | $3.26M 10-K · filed 2024-03-28 |
| 2022-12-31 | $2.38M 10-K · filed 2024-03-28 |
| 2021-12-31 | $785.76K 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.11M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $932.06K 10-Q · filed 2021-08-12 |
| 2020-12-31 | $1.09M 10-K · filed 2022-03-24 |
| 2019-12-31 | $532.71K 10-K · filed 2021-03-10 |
| 2018-12-31 | $59.27K 10-K · filed 2020-03-27 |